Short Interest in Burning Rock Biotech Limited (NASDAQ:BNR) Rises By 5.1%

Burning Rock Biotech Limited (NASDAQ:BNR) saw a significant growth in short interest during the month of July. As of July 15th, there was short interest totalling 41,400 shares, a growth of 5.1% from the June 30th total of 39,400 shares. Currently, 0.5% of the company’s shares are sold short. Based on an average daily trading volume, of 5,900 shares, the days-to-cover ratio is presently 7.0 days.

Hedge Funds Weigh In On Burning Rock Biotech

An institutional investor recently raised its position in Burning Rock Biotech stock. Kynam Capital Management LP increased its stake in Burning Rock Biotech Limited (NASDAQ:BNR) by 10.9% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,640,914 shares of the company’s stock after acquiring an additional 946,488 shares during the period. Burning Rock Biotech makes up about 0.7% of Kynam Capital Management LP’s holdings, making the stock its 18th largest holding. Kynam Capital Management LP owned about 9.41% of Burning Rock Biotech worth $7,020,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 30.03% of the company’s stock.

Burning Rock Biotech Stock Performance

Shares of Burning Rock Biotech stock traded down $0.31 on Thursday, reaching $7.05. The company had a trading volume of 287 shares, compared to its average volume of 6,033. The firm has a market cap of $72.19 million, a PE ratio of -1.14 and a beta of 0.17. The firm’s 50 day moving average price is $6.98 and its two-hundred day moving average price is $7.67. Burning Rock Biotech has a 52-week low of $5.29 and a 52-week high of $21.00.

Burning Rock Biotech (NASDAQ:BNR) last released its quarterly earnings results on Wednesday, May 29th. The company reported ($0.16) EPS for the quarter. Burning Rock Biotech had a negative return on equity of 71.22% and a negative net margin of 113.39%. The firm had revenue of $17.40 million for the quarter.

Burning Rock Biotech Company Profile

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.